Quadrature Capital Ltd Takes Position in Bausch + Lomb Co. (NYSE:BLCO)

Quadrature Capital Ltd acquired a new stake in shares of Bausch + Lomb Co. (NYSE:BLCO - Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 27,317 shares of the company's stock, valued at approximately $526,000.

Several other large investors have also recently added to or reduced their stakes in the stock. Blue Trust Inc. increased its position in Bausch + Lomb by 14,052.2% in the 2nd quarter. Blue Trust Inc. now owns 3,255 shares of the company's stock worth $47,000 after purchasing an additional 3,232 shares during the last quarter. Squarepoint Ops LLC bought a new position in Bausch + Lomb during the second quarter valued at approximately $173,000. Polar Asset Management Partners Inc. acquired a new stake in Bausch + Lomb in the third quarter valued at approximately $289,000. Verition Fund Management LLC acquired a new stake in Bausch + Lomb in the third quarter valued at approximately $302,000. Finally, HighTower Advisors LLC grew its position in Bausch + Lomb by 14.7% in the third quarter. HighTower Advisors LLC now owns 24,661 shares of the company's stock worth $476,000 after acquiring an additional 3,164 shares in the last quarter. Institutional investors and hedge funds own 11.07% of the company's stock.

Analyst Ratings Changes

BLCO has been the subject of several analyst reports. Citigroup lifted their price objective on shares of Bausch + Lomb from $20.00 to $24.00 and gave the company a "buy" rating in a research note on Thursday, October 31st. Morgan Stanley cut Bausch + Lomb from an "overweight" rating to an "equal weight" rating and set a $19.00 price target for the company. in a research report on Monday, December 2nd. Royal Bank of Canada increased their price objective on Bausch + Lomb from $20.00 to $23.00 and gave the company an "outperform" rating in a report on Tuesday, October 22nd. Wells Fargo & Company raised their price objective on Bausch + Lomb from $23.00 to $26.00 and gave the company an "overweight" rating in a research note on Thursday, October 31st. Finally, HC Wainwright upped their target price on Bausch + Lomb from $22.00 to $23.00 and gave the stock a "buy" rating in a research report on Thursday, October 31st. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $21.00.

Bausch + Lomb Trading Down 0.1 %

Shares of BLCO stock traded down $0.02 during trading hours on Monday, reaching $20.05. 562,328 shares of the company's stock were exchanged, compared to its average volume of 547,580. The business has a fifty day moving average price of $19.86 and a 200-day moving average price of $17.39. The company has a quick ratio of 0.95, a current ratio of 1.57 and a debt-to-equity ratio of 0.69. Bausch + Lomb Co. has a fifty-two week low of $13.16 and a fifty-two week high of $21.69.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last released its earnings results on Wednesday, October 30th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of $0.16 by $0.01. The firm had revenue of $1.20 billion during the quarter, compared to analysts' expectations of $1.17 billion. Bausch + Lomb had a negative net margin of 7.86% and a positive return on equity of 3.17%. The business's quarterly revenue was up 18.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.22 EPS. On average, equities analysts predict that Bausch + Lomb Co. will post 0.6 earnings per share for the current year.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.